ArticleCureus2026
A Comparative Evaluation of Dapagliflozin and Sulfonylureas in Patients With Type 2 Diabetes Mellitus.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Type 2 diabetes mellitus (T2DM) often requires combination therapy when metformin alone fails to achieve adequate glycemic control. Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, and glimepiride, a sulfonylurea, are commonly prescribed as add-on therapies. This study compared their efficacy and safety in patients with inadequately controlled T2DM. Methods A nonrandomized prospective observational comparative study was conducted at a tertiary care teaching hospital between April and November 2024. A total of 170 adults with inadequately controlled T2DM receiving metformin (1000 mg) were allocated to receive either dapagliflozin (10 mg) (n=85) or glimepiride (2 mg) (n=85) and were followed for 24 weeks. Primary outcomes included changes in glycated hemoglobin (HbA1c), fasting blood sugar (FBS), and postprandial blood sugar (PPBS). Secondary outcomes included body weight, blood pressure, and adverse events. Results Both treatment groups demonstrated significant improvements in glycemic control over 24 weeks. At study completion, HbA1c was significantly lower in the dapagliflozin group than in the glimepiride group (7.60±0.64% vs. 8.00±0.68%; p=0.01). Glimepiride produced a greater reduction in FBS (101.82±20.65 vs. 115.98±15.09 mg/dL; p<0.001), while PPBS was comparable between groups (p=0.45). Dapagliflozin resulted in significant weight loss and reductions in systolic and diastolic blood pressure, whereas glimepiride was associated with weight gain. Overall, adverse events were more frequent with dapagliflozin, primarily polyuria and genital infections, while hypoglycemia and tremors occurred more frequently with glimepiride. Conclusions Both dapagliflozin and glimepiride were effective as add-on therapy to metformin in improving glycemic control. Dapagliflozin was associated with greater HbA1c reduction, weight loss, lower blood pressure, and a lower risk of hypoglycemia, whereas glimepiride achieved greater fasting glucose reduction. Treatment selection should be individualized based on patient characteristics, comorbidities, and therapeutic goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.